In vivo targeting and multimodal imaging of cerebral amyloid-β aggregates using hybrid GdF 3 nanoparticles

• Published in: Nanomedicine (London, England) England), 2022-12, Vol.17 (29), p.2173-2187
• Main Authors: Lerouge, Frédéric, Ong, Elodie, Rositi, Hugo, Mpambani, Francis, Berner, Lise-Prune, Bolbos, Radu, Olivier, Cécile, Peyrin, Françoise, Apputukan, Vinu K, Monnereau, Cyrille, Andraud, Chantal, Chaput, Frederic, Berthezène, Yves, Braun, Bettina, Jucker, Mathias, Åslund, Andreas Ko, Nyström, Sofie, Hammarström, Per, R Nilsson, K Peter, Lindgren, Mikael, Wiart, Marlène, Chauveau, Fabien, Parola, Stephane
• Format: Article
• Language: English
• Subjects: Alzheimer Disease - diagnostic imaging; Amyloid beta-Peptides - metabolism; Animals; Bioengineering; Brain - diagnostic imaging; Brain - metabolism; Disease Models, Animal; Imaging; Life Sciences; Mice; Mice, Transgenic; Multimodal Imaging; Nanoparticles; Neurobiology; Neurons and Cognition; Rats; Tissue Distribution
• ISSN: 1743-5889; 1748-6963
• DOI: 10.2217/nnm-2022-0252

To propose a new multimodal imaging agent targeting amyloid-β (Aβ) plaques in Alzheimer's disease. A new generation of hybrid contrast agents, based on gadolinium fluoride nanoparticles grafted with a pentameric luminescent-conjugated polythiophene, was designed, extensively characterized and evaluated in animal models of Alzheimer's disease through MRI, two-photon microscopy and synchrotron x-ray phase-contrast imaging. Two different grafting densities of luminescent-conjugated polythiophene were achieved while preserving colloidal stability and fluorescent properties, and without affecting biodistribution. brain uptake was dependent on the blood-brain barrier status. Nevertheless, multimodal imaging showed successful Aβ targeting in both transgenic mice and Aβ fibril-injected rats.